COVID-19 vaccine

Select Long Island Stop & Shop Pharmacies Now Offering Pfizer COVID-19 Vaccine to Customers 12 and Older

Thursday, May 13, 2021 - 9:45pm

b"\xe2\x80\x9cStop & Shop has been proud to support New Yorkers throughout the pandemic, most recently by administering the COVID-19 vaccine,\xe2\x80\x9d said Katie Thornell, Director of Pharmacy Operations at Stop & Shop.

Key Points: 
  • b"\xe2\x80\x9cStop & Shop has been proud to support New Yorkers throughout the pandemic, most recently by administering the COVID-19 vaccine,\xe2\x80\x9d said Katie Thornell, Director of Pharmacy Operations at Stop & Shop.
  • \xe2\x80\x9cWe are excited to begin providing the Pfizer vaccine to our customers as young as twelve years of age to help protect members of the community against COVID-19.\xe2\x80\x9d\nWritten consent from a parent or guardian is required for a trained and trusted Stop & Shop pharmacist to administer the Pfizer vaccine to anyone aged 12 to 18.
  • The coronavirus vaccine is being administered at no out-of-pocket cost.\nDuring immunization, customers will be required to wear PPE and pharmacists will be equipped with masks, gloves, and face shields.
  • Its\xc2\xa0new GO Rewards loyalty program delivers personalized offers and allows customers to earn points that\xc2\xa0can be redeemed for gas or groceries\xc2\xa0every time they shop.

CTT Named 'Best Clinical Trial Site' by World Vaccine Congress

Thursday, May 13, 2021 - 10:00pm

b'SAN ANTONIO, May 13, 2021 /PRNewswire-PRWeb/ -- Clinical Trials of Texas, Inc. (CTT) was named "Best Clinical Site" at the 14th annual Vaccine Industry Excellence (ViE) Awards during the 2021 World Vaccine Congress.\n"CTT is so honored to be recognized for its vaccine work alongside some of the most prestigious names in the pharmaceutical industry," said President/CEO Kay Scroggins, RN.\nCTT has conducted more than 40 vaccine trials including COVID-19, Influenza, Pneumonia, RSV and Meningitis.

Key Points: 
  • b'SAN ANTONIO, May 13, 2021 /PRNewswire-PRWeb/ -- Clinical Trials of Texas, Inc. (CTT) was named "Best Clinical Site" at the 14th annual Vaccine Industry Excellence (ViE) Awards during the 2021 World Vaccine Congress.\n"CTT is so honored to be recognized for its vaccine work alongside some of the most prestigious names in the pharmaceutical industry," said President/CEO Kay Scroggins, RN.\nCTT has conducted more than 40 vaccine trials including COVID-19, Influenza, Pneumonia, RSV and Meningitis.
  • In 2020, CTT was recognized as a top Latino COVID-19 vaccine enroller in an investigational vaccine study.
  • Minority participation in COVID-19 vaccine trials topped 50%, due to ongoing community outreach efforts.
  • CTT conducts studies across Phases I-IV, working with more than 13 investigators across multiple therapeutic areas such as vaccines, metabolic disorders, women\'s health, mental/behavioral health and devices.\n'

The Ad Council and COVID Collaborative's 'It's Up To You' Launching New Efforts to Inspire Vaccine Confidence in Young Adults

Thursday, May 13, 2021 - 3:46pm

Approximately 55 percent of young adults are unsure or disagree that the benefits of COVID vaccines outweigh the risks, a statistic that has remained unchanged over the last few months.

Key Points: 
  • Approximately 55 percent of young adults are unsure or disagree that the benefits of COVID vaccines outweigh the risks, a statistic that has remained unchanged over the last few months.
  • "The campaign is unleashing partners and creative talent to educate and engage young adults so they can make informed decisions about the vaccine.
  • Love Has No Labels.\nThe Ad Council\'s innovative social good campaigns raise awareness, inspire action and save lives.
  • Senator Dirk Kempthorne (R-ID) and former Governor Deval Patrick (D-MA) and led by CEO John Bridgeland and President Gary Edson.

DGAP-News: CureVac : Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study

Thursday, May 13, 2021 - 1:06pm

In addition, the serum of vaccinated animals showed significant cross-neutralization against variants first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa (B.1.351).

Key Points: 
  • In addition, the serum of vaccinated animals showed significant cross-neutralization against variants first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa (B.1.351).
  • "Spurred by the emergence of virus variants that have the potential to affect the efficacy of currently approved first-generation mRNA COVID-19 vaccines, CureVac and GSK aim to jointly develop second-generation vaccine candidates that offer improved immune responses and target emerging variants.
  • Combined with lower doses, these second-generation vaccines could enable also broad protection against selected strains in a multivalent vaccine format.
  • In December 2020, CureVac initiated a pivotal Phase 2b/3, the HERALD study, with a 12\xc2\xb5g dose of CVnCoV.

Community Partners Announce First Vaccination Site for Underserved Youth

Thursday, May 13, 2021 - 11:00am

b'PHOENIX, May 13, 2021 /PRNewswire-PRWeb/ -- The Equality Health Foundation , the HeroZona Foundation and other community partners are excited to announce the launch of the first vaccine site in Arizona for underserved youth ages 12 to 15 at the C.O.

Key Points: 
  • b'PHOENIX, May 13, 2021 /PRNewswire-PRWeb/ -- The Equality Health Foundation , the HeroZona Foundation and other community partners are excited to announce the launch of the first vaccine site in Arizona for underserved youth ages 12 to 15 at the C.O.
  • "We\'ve operated several successful vaccination events and can now give parents and gaurdians in at-risk communities the chance to protect their kids as well.
  • This wouldn\'t be possible without Equality Health Foundation, HeroZona and the other partners committed to keeping our people safe.
  • The third event was held on April 10 at South Mountain Community College, which is now a permanent COVID-19 vaccination site.

COVID-19 Vaccine Age Eligibilty Expands at All Rite Aid Locations

Wednesday, May 12, 2021 - 11:41pm

Those ages 12 through 17 are only authorized to be vaccinated with the Pfizer vaccine, per CDC guidance.\nAdditionally, Rite Aid is enabling schools and organizations in its footprint to inquire about vaccine clinics directly with the company by visiting www.riteaid.com/covid-19/community-clinics .

Key Points: 
  • Those ages 12 through 17 are only authorized to be vaccinated with the Pfizer vaccine, per CDC guidance.\nAdditionally, Rite Aid is enabling schools and organizations in its footprint to inquire about vaccine clinics directly with the company by visiting www.riteaid.com/covid-19/community-clinics .
  • The clinic inquiry tool provides a seamless and efficient way to organize on-site vaccine clinics, helping to bring the vaccine directly into communities and reach people at schools, community centers, churches, and workplaces.
  • Whether it\xe2\x80\x99s COVID-19 testing or vaccine clinics, we\xe2\x80\x99re eager to help our communities thrive.\xe2\x80\x9d\nFor more information about Rite Aid\xe2\x80\x99s COVID-19 vaccine efforts, please visit www.RiteAid.com/covid-19 .\nRite Aid Corporation is on the front lines of delivering healthcare services and retail products to Americans 365 days a year.
  • We provide an array of whole being health products and services for the entire family through over 2,500 retail pharmacy locations across 17 states.

AAFP Celebrates Authorization of COVID-19 Vaccine for Children Ages 12 to 15

Wednesday, May 12, 2021 - 10:53pm

b'"This week marks an important milestone as the first COVID-19 vaccine received emergency use authorization for children ages 12 to 15.

Key Points: 
  • b'"This week marks an important milestone as the first COVID-19 vaccine received emergency use authorization for children ages 12 to 15.
  • Nearly 90 percent of family physicians provide flu and other recommended vaccines to adolescents.
  • The AAFP is encouraged by President Biden\'s intent to distribute vaccines directly to family medicine practices and we look forward to hearing more about the administration\'s plan for implementation.
  • For information about health care, health conditions and wellness, please visit the AAFP\'s award-winning consumer website, www.familydoctor.org .\n'

Cuebiq Partners With The Ad Council and COVID Collaborative To Measure COVID-19 Vaccine Education Initiative

Wednesday, May 12, 2021 - 7:50pm

We\'re fighting two battlesone against COVID-19, the other against misinformation and vaccine hesitancywe need every advantage to overcome the pandemic.

Key Points: 
  • We\'re fighting two battlesone against COVID-19, the other against misinformation and vaccine hesitancywe need every advantage to overcome the pandemic.
  • "\n"This campaign effort takes on one of the most critical issues of our day: increasing confidence in the COVID-19 vaccines.
  • The Ad Council has created many of the most iconic campaigns in advertising history.
  • Tim Shriver is Chairman of UNITE.\nTo learn more, visit http://www.CovidCollaborative.us , and follow the COVID Collaborative on Twitter and LinkedIn.\n'

Sequans and AmericanPharma Technologies Team Up to Protect Covid-19 Vaccine Shipments

Wednesday, May 12, 2021 - 1:00pm

b"Sequans Communications S.A. (NYSE: SQNS) has joined forces with AmericanPharma Technologies and is providing the cellular IoT connectivity solution for AmericanPharma Tech\xe2\x80\x99s PharmaWatch\xe2\x84\xa2 vaccine monitoring system that is currently protecting Covid-19 vaccine shipments and storage around the country.

Key Points: 
  • b"Sequans Communications S.A. (NYSE: SQNS) has joined forces with AmericanPharma Technologies and is providing the cellular IoT connectivity solution for AmericanPharma Tech\xe2\x80\x99s PharmaWatch\xe2\x84\xa2 vaccine monitoring system that is currently protecting Covid-19 vaccine shipments and storage around the country.
  • PharmaWatch comes with sensors preconfigured for the required temperature ranges and can be self-installed in minutes.
  • Monarch is certified by major operators all over the world.\nAmericanPharma Technologies was founded in 2010 when three predecessor companies merged.
  • It alleviates the difficulties inherent in manually monitoring multiple healthcare environments in multiple locations while automatically maintaining complete regulatory compliance.

INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

Wednesday, May 12, 2021 - 1:00pm

These results demonstrate the potential of INOVIO\'s Pan-COVID-19 vaccine to induce cross-reactive immune responses against current and emerging viral variants as either a first-line vaccine, or potentially as a boost for individuals previously immunized with various Wuhan-matched vaccines.\nDr.

Key Points: 
  • These results demonstrate the potential of INOVIO\'s Pan-COVID-19 vaccine to induce cross-reactive immune responses against current and emerging viral variants as either a first-line vaccine, or potentially as a boost for individuals previously immunized with various Wuhan-matched vaccines.\nDr.
  • The study data we report today confirms our two-tiered development path is the best strategy for the short- and long-term fight against this virus.
  • INOVIO\'s Pan-COVID-19 vaccine approach is designed to provide cross-strain protection, immune coverage, reduced susceptibility to escape mutants, and non-restricted geographical use against both known and potentially unknown variants.
  • Preclinical data with INO-4802 in multiple models revealed both broader and increased levels of neutralizing antibodies against a panel of variants than strain-matched vaccines.